PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers-Reference-Cited by-同舟云学术

PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers

Published:2022-05-03 Issue:6 Volume:31 Page:607-631
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Luo Linjie¹^ORCID,Keyomarsi Khandan¹^ORCID

Affiliation:

1. Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX USA

Funder

Cancer Prevention and Research Institute of Texas

National Cancer Institute

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543784.2022.2067527

Reference148 articles.

1. Anders C, Carey LA .Understanding and treating triple-negative breast cancer Oncology (Williston Park NY). 2008 Vol. 22 11 1233 Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers

2. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

3. Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evolving immunotherapeutic solutions for triple-negative breast carcinoma;Cancer Treatment Reviews;2024-11

2. An update on small molecule compounds targeting synthetic lethality for cancer therapy;European Journal of Medicinal Chemistry;2024-11

3. A multi-AS-PCR-coupled CRISPR/Cas12a assay for the detection of ten single-base mutations;Analytica Chimica Acta;2024-09

4. Ovarian cancer: Diagnosis and treatment strategies (Review);Oncology Letters;2024-07-18

5. Deguelin Restores Paclitaxel Sensitivity in Paclitaxel-Resistant Ovarian Cancer Cells via Inhibition of the EGFR Signaling Pathway;Cancer Management and Research;2024-05